Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00175240
Status:
COMPLETED
Last Update Posted:
2015-07-28
First Post:
2005-09-12
Brief Title:
Enhancing the Secondary Prevention of Coronary Artery Disease
Sponsor:
University of Alberta
Organization:
University of Alberta
Study Overview
Official Title:
Enhancing the Use of Secondary Prevention Strategies in Patients With Coronary Artery Disease The ESP-CAD Study
Status:
COMPLETED
Status Verified Date:
2015-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
People with coronary artery disease can reduce their chance of having a heart attack by making healthy lifestyle choices diet exercise quitting smokingetc There are also many medications that have been proven to reduce the risk of heart attacks and may even help people live longer This study will look at different ways of improving the use of these beneficial medications to enhance the quality of care for people with this condition
Detailed Description:
BACKGROUND Despite the abundant evidence base for secondary prevention practice audits consistently demonstrate substantial care gaps between this evidence and clinical reality such that many patients with Coronary Artery Disease CAD are not offered all possible therapies for the prevention of myocardial infarction or death For example even after an acute myocardial infarction almost one fifth of patients continue to smoke over half with hypertension or hyperlipidemia have poorly controlled pressure or lipid levels and proven therapies such as statins ACE inhibitors beta-blockers and antiplatelet agents are under-prescribed
Multiple barriers are often responsible for the lack of implementation of proven efficacious therapies and traditional means of educating practitioners journal articles CME conferences etc are usually ineffective in altering practice Clearly novel interventions to improve the quality of prescribing are needed Local opinion leaders are trusted by their peers to evaluate medical innovations and thus influence practice patterns within their community Few controlled studies however have evaluated their effect on changing prescribing practices for common conditions such as CAD
HYPOTHESIS This trial will test 2 quality improvement interventions The principle hypothesis is does a one-page evidence summary endorsed by local opinion leaders increase the provision of secondary prevention therapies in patients with CAD compared to usual care The secondary hypotheses are does the same intervention but without local opinion leader endorsement improve the provision of secondary prevention strategies in patients with CAD compared to usual care Does local opinion leader endorsement increase the effectiveness of the quality improvement intervention
Multiple barriers are often responsible for the lack of implementation of proven efficacious therapies and traditional means of educating practitioners journal articles CME conferences etc are usually ineffective in altering practice Clearly novel interventions to improve the quality of prescribing are needed Local opinion leaders are trusted by their peers to evaluate medical innovations and thus influence practice patterns within their community Few controlled studies however have evaluated their effect on changing prescribing practices for common conditions such as CAD
HYPOTHESIS This trial will test 2 quality improvement interventions The principle hypothesis is does a one-page evidence summary endorsed by local opinion leaders increase the provision of secondary prevention therapies in patients with CAD compared to usual care The secondary hypotheses are does the same intervention but without local opinion leader endorsement improve the provision of secondary prevention strategies in patients with CAD compared to usual care Does local opinion leader endorsement increase the effectiveness of the quality improvement intervention
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None